Evidence map›Paper›PMID 40272497›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2025

Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children.

Connie Peet, Caroline Elmaraghi, Tarek Abdel-Aziz, Huang Hian Liang, Jennifer E Gains, Trung Nguyen, Simon Wan, Jamshed B Bomanji, Mark N Gaze

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Connie PeetDepartment of Radiotherapy, University College London Hospitals NHS Foundation Trust, London, UK.
Caroline ElmaraghiDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Tarek Abdel-AzizDepartment of Endocrine Surgery, University College London Hospitals NHS Foundation Trust, London, UK.
Huang Hian LiangDepartment of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Jennifer E GainsDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Trung NguyenDepartment of Paediatric Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Simon WanDepartment of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Jamshed B BomanjiDepartment of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Mark N GazeDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, UK. mark.gaze@ucl.ac.uk.ORCID 0000-0002-8344-7902

Funding

Cancer Research UK C7893/A28990
6 · The paper itself

Abstract

purposeParaganglioma, phaeochromocytoma and gastroenteropancreatic neuroendocrine tumours are rare in childhood. Molecular radiotherapy is one potential treatment for locally inoperable or metastatic disease. This study reviews the use and efficacy of molecular radiotherapy with both [

methodsThis is an observational cohort study of all patients aged less than 18 years with adult type metastatic neuroendocrine cancers treated with molecular radiotherapy from 2003 to 2023 in one national referral centre.

resultsTwelve patients, six male and six female, were treated. The median age at diagnosis was 12 years 3 months (range 7 years 11 months to 15 years 5 months), and at first molecular radiotherapy treatment was 13 years 7 months (range 8 years 8 months to 16 years 2 months). Nine had paraganglioma or phaeochromocytoma, three had other neuroendocrine tumours. Three received [

conclusionMolecular radiotherapy can be beneficial, and may provide good disease control for long periods in a proportion of these patients. Combining different radiopharmaceuticals may be of value.

Indexed as

Neuroendocrine Tumors3-IodobenzylguanidineAdolescentChildFemaleHumansMaleNeoplasm MetastasisOctreotideOrganometallic Compounds3-Iodobenzylguanidinelutetium Lu 177 dotatateOctreotideOrganometallic CompoundsLutetium DOTATATEMeta iodobenzylguanidineMolecular radiotherapyNeuroendocrine tumoursPaediatricPhaeochromocytoma and paraganglioma

Identifiers

PMID40272497
PMCPMC12397108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.